These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 22406655

  • 1. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Pétain A, Nguyen L.
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G.
    Clin Cancer Res; 2011 Nov 01; 17(21):6867-77. PubMed ID: 21918171
    [Abstract] [Full Text] [Related]

  • 3. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C.
    Bone Marrow Transplant; 2004 May 01; 33(10):979-87. PubMed ID: 15064687
    [Abstract] [Full Text] [Related]

  • 4. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, Mechinaud F, Galambrun C, Neven B, Zouabi H, Nguyen L, Puozzo C.
    Cancer Chemother Pharmacol; 2008 Jan 01; 61(1):113-23. PubMed ID: 17393167
    [Abstract] [Full Text] [Related]

  • 5. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L, Leger F, Lennon S, Puozzo C.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):191-8. PubMed ID: 16133536
    [Abstract] [Full Text] [Related]

  • 6. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, Przepiorka D, Mezzi K, Kletzel M, Pediatric Blood, Marrow Transplant Consortium.
    Pediatr Blood Cancer; 2010 Feb 01; 54(2):291-8. PubMed ID: 19743300
    [Abstract] [Full Text] [Related]

  • 7. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
    Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, Doz F, Neven B, Bertrand Y, Galambrun C, Demeocq F, Yakouben K, Bordigoni P, Frappaz D, Nguyen L, Vassal G.
    Pediatr Blood Cancer; 2012 Jan 01; 58(1):90-7. PubMed ID: 21254374
    [Abstract] [Full Text] [Related]

  • 8. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
    Ben Hassine K, Nava T, Théoret Y, Nath CE, Daali Y, Kassir N, Lewis V, Bredius RGM, Shaw PJ, Bittencourt H, Krajinovic M, Uppugunduri CRS, Ansari M.
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep 01; 10(9):1043-1056. PubMed ID: 34453497
    [Abstract] [Full Text] [Related]

  • 9. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
    Nguyen L.
    Fundam Clin Pharmacol; 2008 Dec 01; 22(6):599-604. PubMed ID: 19049661
    [Abstract] [Full Text] [Related]

  • 10. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM, Egeler RM, den Hartigh J, Vossen JM.
    Bone Marrow Transplant; 2005 Jan 01; 35(1):17-23. PubMed ID: 15502853
    [Abstract] [Full Text] [Related]

  • 11. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep 01; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 12. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP.
    Biol Blood Marrow Transplant; 2004 Sep 01; 10(9):614-23. PubMed ID: 15319773
    [Abstract] [Full Text] [Related]

  • 13. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y, Kato K, Le Gallo C, Armstrong E, Rock E, Wang X.
    Cancer Chemother Pharmacol; 2015 Mar 01; 75(3):505-12. PubMed ID: 25561350
    [Abstract] [Full Text] [Related]

  • 14. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M, Gravina P, Sodani P, Marziali M, Isgrò A, Simone MD, Andreani M, Formosa A, Testi M, Federici G, Bernardini S, Lucarelli G.
    Blood; 2010 Jun 03; 115(22):4597-604. PubMed ID: 20237319
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M, Jacobsohn D, Duerst R.
    Biol Blood Marrow Transplant; 2006 Apr 03; 12(4):472-9. PubMed ID: 16545731
    [Abstract] [Full Text] [Related]

  • 16. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.
    Ther Drug Monit; 2014 Feb 03; 36(1):93-9. PubMed ID: 24061446
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar 03; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 18. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P, Park JJ, DeFor TE, Thrall M, Abel S, Krivit W, Peters C.
    Bone Marrow Transplant; 2001 Apr 03; 27(8):855-61. PubMed ID: 11477444
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW.
    Biol Blood Marrow Transplant; 2004 Nov 03; 10(11):805-12. PubMed ID: 15505611
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.